

Same as 29A box E
Delete

~~29. The method of claim 28, wherein the alloimmune response is a human anti-HLA alloimmune response.~~

a1 SUB
D+
Candide
30. The method of claim 27, for treating or preventing a disease selected from the group consisting of systemic lupus erythematosus (SLE), sjögren's syndrome, scleroderma myositis, Raynaud's syndrome, type 1 diabetes, arthritis and rheumatoid arthritis, inflammatory bowel disease, uveitis, myasthenia gravis, multiple sclerosis, idiopathic thrombocytopenic purpura and graft vs host disease as well as allergies which are dependent on T cells.

31. A method for testing *in vivo* effects of an immunotherapy or inhibition of a human antibody response in an immunodeficient mouse model of human alloimmunization, comprising subjecting the mouse to immunotherapy or inhibition of a human antibody response, said mouse being an immunodeficient mouse and reconstituted with human peripheral blood lymphocytes (PBL) from donors.

32. The method of claim 31, wherein the immunodeficient mouse is γ -irradiated and asialoGM₁ treated for enhancing cellular engraftment.


33. The method of claim 31, wherein the donors are sensitized to HLA antigens.--

REMARKS

Claim 1 has been canceled and new claims 24-33 added. Support for these new claims can be found throughout the specification and their entry is respectfully requested.

Early examination and allowance is respectfully requested.

Respectfully submitted,


David S. Resnick, Reg. No. 34,235
Nixon Peabody LLP
101 Federal Street
Boston, MA 02110
(617) 345-6057

5/26/2000

09579548 052600